Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on March 6 and set a price target of ...
In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...
The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
FRANKFURT (Reuters) - Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by ...
Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...
Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.
Include popular icons in your React projects easily with react-icons, which utilizes ES6 imports that allows you to include only the icons that your project is using. For example, to use an icon from ...
Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...
→ Peter Guenter will retire as CEO of Merck KGaA’s healthcare business on June 1, one of several personnel moves that the German pharma … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback